Medical Decision Making

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noyes, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noyes, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Medical Decision Making, Vol. 24, No. 5, 472-485 (2004)
DOI: 10.1177/0272989X04268960

Pramipexole v. Levodopa as Initial Treatment for Parkinson’s Disease: A Randomized Clinical-Economic Trial

Katia Noyes, PhD, MPH

Andrew W. Dick, PhD

Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York.

Robert G. Holloway, MD, MPH,

Department of Community and the Department of Neurology, University of Rochester School of Medicine, Rochester, New York; 601 Elmwood Ave., Box 673, Rochester, NY 14642; telephone: (585) 273-4241robert.holloway{at}ctcc.rochester.edu

Parkinson Study Group

Purpose.To determine the 2-year incremental cost effectiveness of initial pramipexole treatment compared with initial levodopa treatment in patientswith early Parkinson’s disease (PD).Methods.301 subjects with early PD were randomized to either pramipexole or levodopa and followed every 3 months over a 2-year period. Costs were assigned to patient collected health utilization data using a variety of methods. Health state preferences were estimated using the EuroQol.Results.Pramipexole strategy was an estimated $2,138 (SE = $1,182) more expensive than levodopa strategy. The incremental cost-effectiveness of pramipexole compared with levodopa was $106,900/QALY (EQ-5D), compared with pramipexole being dominated by levodopa using the EQVAS.Conclusions.Although considerable uncertainty exists in the 2-year cost-effectiveness of initial pramipexole compared with initial levodopa in the treatment of early PD, our estimates suggest that pramipexole may not be welfare enhancing during the first 2 years of treatment. If initial pramipexole results in long-term improvements in quality of life, its cost-effectiveness will become more favorable.

Key Words: Parkinson’s disease • levodopa • pramipexole • randomized clinical trials • quality of life • cost-effectiveness • net benefit • societal welfare


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 PNHome page
Y. Bravo Vergel and M. Sculpher
Quality-adjusted life years
Practical Neurology, June 1, 2008; 8(3): 175 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
K. Noyes, A. W. Dick, and R. G. Holloway
The Implications of Using US-Specific EQ-5D Preference Weights for Cost-Effectiveness Evaluation
Med Decis Making, May 1, 2007; 27(3): 327 - 334.
[Abstract] [PDF]

Home page
 StrokeHome page
L. S. Williams and R. G. Holloway
Editorial Comment: How Much Is a Good Night's Sleep Worth?
Stroke, June 1, 2005; 36(6): 1293 - 1294.
[Full Text] [PDF]